What the research found
A systematic review synthesizing 14 studies with nearly 1,400 men found that testosterone replacement therapy produced measurable improvements across most tracked outcomes in hypogonadal individuals. Benefits were observed in erectile function, sexual symptoms, fatigue, lean muscle mass, fat mass, and waist circumference, as well as self-reported quality of life. Lower urinary tract symptoms showed no consistent pattern of improvement.
The analysis revealed important differences depending on how studies were designed. Randomised controlled trials—the gold standard for causal inference—generally showed smaller effect sizes than observational studies, which tend to overestimate benefits. Heterogeneity (variation between studies) was substantial for sexual function, symptom relief, and urinary outcomes, meaning responses likely differ significantly between individuals. Fatigue and quality-of-life improvements were more consistent across studies.
Why it matters for you
If you're considering or already on TRT, this summary suggests you should expect genuine but variable changes. Improvements in body composition—lean mass gain and fat loss—align with what many users track via DEXA scans or bioelectrical impedance. The modest but consistent fatigue reduction is worth monitoring against your own energy logs or training recovery metrics. However, the sex-performance benefits may not materialise uniformly; individual response varies considerably.
The gap between trial and observational findings is worth taking seriously. If you're reading anecdotal reports online of dramatic transformations, remember those are self-selected reports; controlled settings show more modest gains. If you're tracking metrics like waist circumference, body composition, or symptom questionnaires, you have a practical way to assess whether you personally are responding as expected.
The lack of clear benefit for urinary symptoms means you shouldn't expect TRT to solve lower urinary tract issues independently—those may need separate evaluation if they're present.
Caveats
- Observational studies inflated estimates: Comparing uncontrolled groups likely overstates real effects; randomised trials showed smaller benefits
- High heterogeneity: Variation between studies suggests outcomes aren't universal; your results may differ from pooled averages
- Study quality not specified: Unclear whether included trials used proper blinding, adequate dosing protocols, or long follow-up periods
- Short-term focus likely: Meta-analyses typically capture shorter interventions; long-term safety and efficacy remain less certain
- No breakdown by baseline testosterone level: Outcomes may differ between moderately and severely hypogonadal men